Formulation and characterization of brucea javanica oil microemulsion

摘要

Objective This study engaged in investigation of optimal formulation,characteristics analysis of Brucea javanica oil microemulsion(BJOM) in order to address safety concerns and make recommendations for improvements in BJOM safety during clinical use in vivo.Methods Pseudo-ternary phase diagram techniques were used to determine the appropriate ratio of surfactant,cosurfactant,and oil phases.Subsequent stability testing of BJOM was performed by dilution,centrifugation,and accelerated stability testing.The results were expounded through additional assessment utilizing the classical thermostat method to establish the shelf life of the material.These results were utilized to evaluate the safety of BJOM by haemolytic,irritative and allergic testing in vitro.In addition,the cytotoxicity of BJOM was examined using the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide(MTT),with particular emphasis given to potential uses in cancer treatment.Results The most suitable method of preparation for BJOM was found to be a one to one ratio(Km 1∶ 1) of Solutol HS15 surfactant matched with sorbitol cosurfactant in the ratio.The microemulsion droplets of BJOM possessed a spherical shape,uniform size,and average diameter of 23.8nm.The expiration date of BJOM was found to be 568d.The safety study demonstrated no haemolysis activity at the experimental BJOM concentrations;however,mild haemolysis was observed at higher concentrations of Brucea javanica oil emulsion(BJOE),a common commercially available product.Irritation observed upon BIOM treatment can be primarily attributed to Brucea javanica oil(BJO) with little influence of BJOM excipients.In addition,BJOM caused no observed hypersensitivity or other visible allergic reactions in guinea pigs.The anticancer activity curves of BJOM and BJOE demonstrate that both BJOM and BJOE inhibit Hela cells,with BIOM demonstrating significantly more dramatic anticancer activity.Conclusion An optimal formulation of BJOM superior to commercially available products and safe for medical application such as intravenous injection has been outlined along with its anticancer activity rating.